For millions of people living with osteoarthritis, the daily reality is defined by persistent pain, deep stiffness, and a gradual loss of mobility that makes even the most routine activities increasingly difficult. Standard medical interventions, ranging from over-the-counter anti-inflammatory medications to targeted steroid injections, can often reduce symptoms for a temporary window. However, none of these conventional treatments possess the ability to alter the underlying trajectory of the disease or prevent the progressive structural damage occurring deep within the joint.
Now, a team of researchers at Yale University has pointed toward a fundamentally different approach. In a study recently published in the scientific journal Bioactive Materials, investigators demonstrated that an existing pharmaceutical medication, lacosamide, can perform a dual role in osteoarthritis management: simultaneously alleviating joint pain while actively reversing cartilage degradation. Furthermore, the therapeutic effects were shown to be exceptionally powerful when the drug was delivered precisely into the joint cavity utilizing a specially engineered temperature-sensitive hydrogel.
Why Osteoarthritis Damages Cartilage
Osteoarthritis is frequently described in colloquial terms as a condition driven purely by standard wear and tear, but medical experts emphasize that this description leaves out much of the complex biological machinery at play. Within a healthy human joint, specialized cellular entities known as chondrocytes maintain the structural integrity of cartilage through a continuous, delicate balance. They constantly weigh the creation of new extracellular matrix tissue against the enzymatic removal and remodeling of old material.
Osteoarthritis fundamentally disrupts that critical balance. Under the influence of the disease, cartilage begins to break down at a rate far faster than the chondrocytes can possibly replace it. Over time, this imbalance thins the protective cushioning entirely, eventually allowing adjacent bones to grind directly against one another. As the condition advances into its later stages, many patients experience debilitating chronic pain and loss of function, ultimately requiring invasive joint reconstruction procedures such as a total knee replacement.
"There is a major unmet need in osteoarthritis," explains the study’s principal investigator, Chuan-Ju Liu, PhD, who serves as the Charles W. Ohse Professor of Orthopaedics & Rehabilitation at Yale. "We need therapies that don’t just mask pain but actually change how the disease progresses."
At the present time, no pharmaceutical product approved by the U.S. Food and Drug Administration holds an indication to both stop osteoarthritis pain and prevent or reverse the structural breakdown of joint cartilage. The innovative work led by Liu and his research team suggests that it may soon be possible to tackle both facets of the pathology using a single, cohesive therapeutic strategy.
By successfully repurposing an established medication and pairing it with an advanced biomaterial designed to anchor the drug securely inside the joint, the researchers have mapped out a pathway that could preserve vital joint tissue while delivering sustained, long-term pain relief without any reliance on addictive opioid medications.
A Protein Linked to Pain and Cartilage Loss
The core of the Yale discovery centers around a specific protein designated as Nav1.7, which functions biologically as a voltage-gated sodium channel. These cellular channels act essentially as microscopic gates embedded within cell membranes, playing a critical role in generating and propagating electrical signaling throughout various types of tissue.
For years, the scientific and medical communities believed that Nav1.7 operated primarily within specialized peripheral nerve cells dedicated to transmitting pain signals upward to the central nervous system. However, more recent investigative work conducted by Liu and his laboratory team revealed a surprising twist: the protein is also highly active within chondrocytes, the very cells tasked with producing and maintaining joint cartilage.
In a healthy joint, Nav1.7 remains relatively quiet and subdued. In an osteoarthritic joint, however, its activity increases substantially. The researchers discovered that this heightened protein activity does double duty in a destructive way, intensifying pain signaling while simultaneously pushing chondrocytes toward actively breaking down the cartilage matrix they would normally protect and preserve.
This dual involvement makes Nav1.7 an unusually promising therapeutic target, as it clearly influences both the subjective neurological sensation of pain and the physical structural deterioration of the joint tissue itself.
"When Nav1.7 becomes dysregulated, it contributes to both joint degeneration and pain," Liu notes. "Our findings suggest that Nav1.7 is a dual-acting target. By blocking this single protein, we can potentially quiet the pain nerves and tell the cartilage cells to not only stop breaking down but start repairing as well."
Epilepsy Drug Shows Potential for Cartilage Repair
Rather than spending years attempting to design and synthesize an entirely new chemical entity from scratch, Liu’s team decided to test existing pharmacological agents that are already known to inhibit sodium channels. Among the various candidates evaluated, the medication lacosamide produced exceptionally strong biological effects at considerably lower concentrations, while also offering a vastly superior safety profile compared to older, legacy drugs in the same pharmaceutical class.
Lacosamide is already widely recognized and prescribed as a safe and effective treatment for managing epilepsy in human patients. However, when the Yale researchers analyzed its interaction with cartilage cells, they discovered that its therapeutic performance depended heavily on precise dosing parameters.
Interestingly, more medicine was not automatically better. At an ideal, finely tuned low concentration, lacosamide strongly encouraged cells to upregulate proteins involved in building new cartilage while simultaneously suppressing the destructive enzymatic processes that break tissue down. When the drug concentration strayed outside this narrow window—either becoming too high or dropping too low—the beneficial effects rapidly began to fade.
"This tells us the system is finely tuned," Liu observes. "There is an optimal range where the drug helps restore balance without overcorrecting. What stood out was not just its effectiveness, but how little of a dose was needed."
Further biochemical investigation revealed that lacosamide also alters intercellular communication mechanisms. The drug actively stimulated the release of two highly beneficial signaling proteins into the cellular environment: HSP70 and midkine.
HSP70 assists cells in mounting a proper response against physiological stress while directly supporting tissue repair, whereas midkine helps regulate localized inflammation and protect delicate joint tissue from further degeneration. Working in tandem, these proteins appear to establish an extracellular microenvironment that is substantially more favorable for long-term cartilage maintenance and preservation.
"These proteins create a supportive environment for cartilage maintenance," Liu explains. "They allow the effects of the drug to extend beyond individual cells and influence the entire tissue."
Smart Hydrogel Keeps the Drug Inside the Joint
During preclinical testing, oral administration of lacosamide demonstrated promising therapeutic activity. However, medications taken conventionally by mouth must circulate systemically throughout the entire human body, a factor that inherently increases the potential for unwanted off-target side effects in other organ systems.
To circumvent this limitation, the researchers investigated the utility of intra-articular injection, a technique that places the liquid medication directly inside the affected joint cavity. Even this method presented a significant physiological hurdle that needed to be addressed.
"The knee joint, which is also the most common location for osteoarthritis, naturally acts like a leaky bucket," Liu points out. "The body’s lymphatic and circulatory drainage systems can clear out standard liquids injected into the knee within hours."
To keep the medication localized and active for an extended period, the Yale team engineered a specialized, temperature-responsive hydrogel constructed from Collagen II. This advanced biomaterial possesses unique physical properties: it remains in a free-flowing liquid state while contained inside a cool medical syringe, but swiftly transitions into a firm, cohesive, jelly-like matrix the moment it reaches normal human body temperature.
Once deployed inside the joint environment, the gel functions as a localized storage depot for the lacosamide. It holds the pharmaceutical cargo securely in the specific anatomical region where it is needed most, releasing the medication in a slow, controlled, and sustained manner over the course of several weeks.
"The hydrogel acts as a local reservoir," Liu says. "It holds the drug in place in the location it is needed most and releases it slowly over time. It transforms a daily pill into a long-lasting, local treatment that stays active for a month or longer."
In concurrent preclinical studies, administering a single injection of the lacosamide-loaded hydrogel once every four weeks successfully prevented cartilage loss more effectively than requiring an animal model to take a daily oral dose of the drug.
Existing Drug Could Speed Clinical Testing
One of the most consequential advantages of focusing on lacosamide is the fact that the medication already holds full regulatory approval for human use. This established clinical history could potentially make it possible for researchers to advance toward formal clinical trials in human osteoarthritis patients much more rapidly than would ever be feasible with a completely novel experimental compound.
Furthermore, lacosamide has already undergone human clinical evaluation for certain nerve-related pain conditions linked to specific Nav1.7 mutations. Those prior human safety and efficacy data provide the Yale research team with a greater degree of confidence that the promising results observed in laboratory settings could eventually translate into meaningful, long-lasting pain relief and tissue protection for human patients.
This scientific endeavor also illustrates a broader, increasingly important directional shift in modern medicine: combining repurposed pharmacological agents with sophisticated biomaterials to exert precise control over where and how treatments are delivered within the body. If this localized delivery approach ultimately proves successful in human clinical trials, it could dramatically reduce the number of invasive joint procedures patients require, limit systemic side effects, and offer enduring protection against structural joint deterioration.
"我们不是仅仅在开发一种治疗方法," Liu concludes, summarizing the long-term vision of the research. "We are developing a system that allows the medicine to work more effectively where it matters most. Our goal is to move beyond symptom control and towards true disease modification. This effort brings us closer to that reality."